Evidence map›Paper›PMID 30151369›Full record

ArticleERJ open research2018

Metformin added to bosentan therapy in patients with pulmonary arterial hypertension associated with congenital heart defects: a pilot study.

Shutan Liao, Dongsheng Li, Zheng Hui, Craig S McLachlan, Yang Zhang

2 registry-linked trialsOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ERJ open research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05853601 phase1 / phase2active not recruitingnot on this mapstarted 2023, after this paper: background citation

Theophylline Prophylaxis During Hypothermia to Limit Neonatal Nephron Damage

TypeinterventionalSponsorMedical College of WisconsinRan2023 to 2027Enrolled30ConditionsAcute Kidney Injury, HIEArmsSingle Dose Theophylline, Repeat Dose Theophylline
NCT07120971 early_phase1recruitingnot on this mapstarted 2025, after this paper: background citation

A Phase 0/Phase 1 Trial of Metformin for Premature Infants With Bronchopulmonary Dysplasia

TypeinterventionalSponsorMedical College of WisconsinRan2025 to 2030Enrolled40ConditionsBronchopulmonary Dysplasia (BPD)ArmsMetformin (open-label)
3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. A Systematic Review of Novel Therapies of Pulmonary Arterial Hypertension.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2024
    Pooled it
  2. Review
  3. Review
  4. Review
  5. Circulation research · 2022
    Article
  6. Review
  7. Review
  8. Lessons from Cancer Metabolism for Pulmonary Arterial Hypertension and Fibrosis.American journal of respiratory cell and molecular biology · 2021
    Review
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 5 institutions in 2 countries.

Shutan LiaoRural Clinical School, University of New South Wales, Sydney, Australia.
Dongsheng LiThe First Affiliated Hospital of Nanchang University, Nanchang, China.
Zheng HuiThe First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Craig S McLachlanRural Clinical School, University of New South Wales, Sydney, Australia.
Yang ZhangThe First Affiliated Hospital of Nanchang University, Nanchang, China.
First Affiliated Hospital of Nanchang University · CNNanchang University · CNSun Yat-sen University · CNThe First Affiliated Hospital, Sun Yat-sen University · CNUNSW Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pulmonary arterial hypertension (PAH) is a common complication of a congenital heart defect (CHD). Recent studies suggest metformin may be a potential drug to improve cardiac function in PAH. A pilot study was conducted to investigate the efficacy of short-term treatment with a combination regimen consisting of bosentan and metformin in PAH-CHD patients as compared with bosentan monotherapy in a prospective, randomised study. Patients with PAH-CHD were randomised to receive bosentan (initially at 62.5 mg twice daily for 4 weeks and then 125 mg twice daily) for 3 months with or without the combination treatment of metformin (500 mg twice daily). 93 patients were enrolled to bosentan monotherapy (n=48) or bosentan/metformin combination treatment (n=45). After 3 months, both treatments significantly improved World Health Organization functional class, 6-min walking distance (6MWD), N-terminal pro-brain natriuretic peptide and right heart haemodynamic parameters. The improvements in 6MWD and pulmonary vascular resistance index were significantly greater in patients treated with combination therapy than in those who received monotherapy (mean±sd 95±136

Identifiers

PMID30151369
PMCPMC6104295
OpenAlexW2888327442

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.